NutritionArrayit Corporation Addresses Flu Pandemic
Arrayit Corporation (OTCBB: ARYC), a leading manufacturer of products and services for disease prevention, treatment and cure, announced that its microarray-based diagnostic test, patented under the trade name Variation Identification Platform (VIP), is ready for manufacture and distribution. A breakthrough screening test using VIP will allow clinicians and researchers to test and detect the H1N1 swine flu virus in population wide studies.
The World Health Organization (WHO) announced on June 11, that the threat level of the H1N1 swine flu virus is now a global pandemic. This news is ideally timed with Arrayit Corporation"s release of its patented VIP screening test.
The Arrayit test will allow researchers and clinicians to detect the presence of the new H1N1 virus in mass numbers of flu patients, and to distinguish this threatening mutated strain from less harmful variants. Arrayit"s first supplies will be sent to the Centers for Disease Control (CDC) in Atlanta to be approved for use in the USA. Shortly thereafter, the H1N1 test kits will be made available for emergency use by licensed clinics, laboratories and other health care organizations worldwide.
The VIP screening test is the first of its kind developed for multiple numbers of test subjects, with diagnosis available to patients within hours of testing. Up to 80,000 patients can be screened at a time, making it possible for entire communities and entire countries to quickly identify those infected with the new H1N1 virus. The ability to test and quickly diagnose mass numbers of subjects allows health clinicians the opportunity to gain control of the spread of the virus in a shorter time frame than current individual testing procedures. The VIP test kits will be made available at an affordable cost (estimated at under $50 per individual), making it feasible even for those without health insurance coverage to be screened.
Arrayit Corporation